Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Jan;34(1):e70082.
doi: 10.1002/pds.70082.

Safety Assessment of Influenza Vaccination for Neurological Outcomes Among Older Adults in Japan: A Self-Controlled Case Series Study

Mitsunori Ogawa  1 , Yoshinori Takeuchi  2   3 , Yukino Iida  4   5 , Masao Iwagami  6 , Kohei Uemura  1 , Sachiko Ono  7 , Nobuaki Michihata  8 , Daisuke Koide  9 , Yutaka Matsuyama  3 , Hideo Yasunaga  10
Affiliations
Observational Study

Safety Assessment of Influenza Vaccination for Neurological Outcomes Among Older Adults in Japan: A Self-Controlled Case Series Study

Mitsunori Ogawa et al. Pharmacoepidemiol Drug Saf. 2025 Jan.

Abstract

Purpose: To assess adverse neurological risks following influenza vaccination in older adults.

Methods: Using a linked database of healthcare administrative claims data and vaccination records from an urban city in Japan (April 1, 2014, to March 31, 2020), we conducted an observational study utilizing a self-controlled case series design. We identified individuals aged ≥ 65 years who experienced adverse neurological outcomes, defined as hospitalizations related to epilepsy, paralysis, facial paralysis, neuralgia, neuritis, optic neuritis, migraine, extrapyramidal disorders, Guillain-Barre syndrome, or narcolepsy. We used conditional Poisson regression to analyze within-subject incidence rate ratios, comparing the risk of these outcomes during risk periods following influenza vaccination (0-6 days and 7-29 days after each vaccination) with nonvaccination periods. Our analysis was adjusted for age and season groups as time-varying covariates.

Results: We enrolled 3283 eligible individuals (men: 1643; mean [standard deviation] age: 76 [7.3] years). The incidence rate ratio for the outcome during the risk periods was 0.93 (95% confidence interval, 0.66-1.30) in risk period 1 (0-6 days after vaccination) and 1.14 (0.96-1.35) in risk period 2 (7-29 days after vaccination), respectively.

Conclusions: We found no evidence that the risk of adverse neurological events was increased after influenza vaccination in older adults. These results may help reassure older adults who are hesitant to receive influenza vaccination because of concerns regarding adverse neurological outcomes.

Keywords: neurology; observational study; pharmacoepidemiology; self‐controlled study design; vaccine safety.

PubMed Disclaimer

Conflict of interest statement

Y.T. had received consultant fees from Pharmaceuticals and Medical Devices Agency, EPARK Inc. and EPS Corporation. Y.T. has been conducting a collaborative study with Pfizer Inc. which is not related to this study. The remaining authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Graphical representation of the study timeline.
FIGURE 2
FIGURE 2
Flow diagram of participant selection for outcomes based on all neurological diseases.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wong C. M., Chan K. P., Hedley A. J., and Peiris J. S. M., “Influenza‐Associated Mortality in Hong Kong,” Clinical Infectious Diseases 39, no. 11 (2004): 1611–1617, 10.1086/425315. - DOI - PubMed
    1. Thompson W. W., Comanor L., and Shay D. K., “Epidemiology of Seasonal Influenza: Use of Surveillance Data and Statistical Models to Estimate the Burden of Disease,” Journal of Infectious Diseases 194, no. S2 (2006): S82–S91, 10.1086/507558. - DOI - PubMed
    1. Rothberg M. B., Haessler S. D., and Brown R. B., “Complications of Viral Influenza,” American Journal of Medicine 121, no. 4 (2008): 258–264, 10.1016/j.amjmed.2007.10.040. - DOI - PMC - PubMed
    1. Chung H., Buchan S. A., Campigotto A., et al., “Influenza Vaccine Effectiveness Against all‐Cause Mortality Following Laboratory‐Confirmed Influenza in Older Adults, 2010–2011 to 2015–2016 Seasons in Ontario, Canada,” Clinical Infectious Diseases 73, no. 5 (2021): e1191–e1199, 10.1093/cid/ciaa1862. - DOI - PMC - PubMed
    1. Kajikawa N., Kataoka Y., Goto R., et al., “Factors Associated With Influenza Vaccination in Japanese Elderly Outpatients,” Infection, Disease & Health 24, no. 4 (2019): 212–221, 10.1016/j.idh.2019.07.002. - DOI - PubMed

Publication types

Substances